COVID-19 Impact on Global Urological Cancer Therapeutics Drugs, Market Insights and Forecast to 2026

COVID-19 Impact on Global Urological Cancer Therapeutics Drugs, Market Insights and Forecast to 2026

Jun 2020 QYResearch Pharmaceutical152 Pages Price :
$ 3900
Urological Cancer Therapeutics Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Urological Cancer Therapeutics Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Urological Cancer Therapeutics Drugs market is segmented into
Xofigo (radium Ra 223 dichloride)
Jevtana (cabazitaxel)
Inlyta (axitinib)
Votrient (pazopanib hydrochloride)
Sutent (sunitinib malate)
Zytiga (abiraterone acetate)
Xtandi (enzalutamide)
Opdivo (nivolumab)
Provenge (sipuleucel-T)

Segment by Application, the Urological Cancer Therapeutics Drugs market is segmented into
Hospital
Medical Research Laboratory
Others

Regional and Country-level Analysis
The Urological Cancer Therapeutics Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Urological Cancer Therapeutics Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Urological Cancer Therapeutics Drugs Market Share Analysis
Urological Cancer Therapeutics Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Urological Cancer Therapeutics Drugs business, the date to enter into the Urological Cancer Therapeutics Drugs market, Urological Cancer Therapeutics Drugs product introduction, recent developments, etc.
The major vendors covered:
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline plc
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
1 Study Coverage
1.1 Urological Cancer Therapeutics Drugs Product Introduction
1.2 Market Segments
1.3 Key Urological Cancer Therapeutics Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Type
1.4.2 Xofigo (radium Ra 223 dichloride)
1.4.3 Jevtana (cabazitaxel)
1.4.4 Inlyta (axitinib)
1.4.5 Votrient (pazopanib hydrochloride)
1.4.6 Sutent (sunitinib malate)
1.4.7 Zytiga (abiraterone acetate)
1.4.8 Xtandi (enzalutamide)
1.4.9 Opdivo (nivolumab)
1.4.10 Provenge (sipuleucel-T)
1.5 Market by Application
1.5.1 Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Medical Research Laboratory
1.5.4 Others
1.6 Coronavirus Disease 2019 (Covid-19): Urological Cancer Therapeutics Drugs Industry Impact
1.6.1 How the Covid-19 is Affecting the Urological Cancer Therapeutics Drugs Industry
1.6.1.1 Urological Cancer Therapeutics Drugs Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Urological Cancer Therapeutics Drugs Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Urological Cancer Therapeutics Drugs Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Urological Cancer Therapeutics Drugs Market Size Estimates and Forecasts
2.1.1 Global Urological Cancer Therapeutics Drugs Revenue 2015-2026
2.1.2 Global Urological Cancer Therapeutics Drugs Sales 2015-2026
2.2 Urological Cancer Therapeutics Drugs Market Size by Region: 2020 Versus 2026
2.2.1 Global Urological Cancer Therapeutics Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Urological Cancer Therapeutics Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Urological Cancer Therapeutics Drugs Competitor Landscape by Players
3.1 Urological Cancer Therapeutics Drugs Sales by Manufacturers
3.1.1 Urological Cancer Therapeutics Drugs Sales by Manufacturers (2015-2020)
3.1.2 Urological Cancer Therapeutics Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Urological Cancer Therapeutics Drugs Revenue by Manufacturers
3.2.1 Urological Cancer Therapeutics Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Urological Cancer Therapeutics Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Urological Cancer Therapeutics Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Urological Cancer Therapeutics Drugs Revenue in 2019
3.2.5 Global Urological Cancer Therapeutics Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Urological Cancer Therapeutics Drugs Price by Manufacturers
3.4 Urological Cancer Therapeutics Drugs Manufacturing Base Distribution, Product Types
3.4.1 Urological Cancer Therapeutics Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Urological Cancer Therapeutics Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Urological Cancer Therapeutics Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)
4.1 Global Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020)
4.1.1 Global Urological Cancer Therapeutics Drugs Sales by Type (2015-2020)
4.1.2 Global Urological Cancer Therapeutics Drugs Revenue by Type (2015-2020)
4.1.3 Urological Cancer Therapeutics Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Urological Cancer Therapeutics Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Urological Cancer Therapeutics Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Urological Cancer Therapeutics Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Urological Cancer Therapeutics Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Breakdown Data by Application (2015-2026)
5.1 Global Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020)
5.1.1 Global Urological Cancer Therapeutics Drugs Sales by Application (2015-2020)
5.1.2 Global Urological Cancer Therapeutics Drugs Revenue by Application (2015-2020)
5.1.3 Urological Cancer Therapeutics Drugs Price by Application (2015-2020)
5.2 Urological Cancer Therapeutics Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Urological Cancer Therapeutics Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Urological Cancer Therapeutics Drugs Price Forecast by Application (2021-2026)

6 North America
6.1 North America Urological Cancer Therapeutics Drugs by Country
6.1.1 North America Urological Cancer Therapeutics Drugs Sales by Country
6.1.2 North America Urological Cancer Therapeutics Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Urological Cancer Therapeutics Drugs Market Facts & Figures by Type
6.3 North America Urological Cancer Therapeutics Drugs Market Facts & Figures by Application

7 Europe
7.1 Europe Urological Cancer Therapeutics Drugs by Country
7.1.1 Europe Urological Cancer Therapeutics Drugs Sales by Country
7.1.2 Europe Urological Cancer Therapeutics Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Urological Cancer Therapeutics Drugs Market Facts & Figures by Type
7.3 Europe Urological Cancer Therapeutics Drugs Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Urological Cancer Therapeutics Drugs by Region
8.1.1 Asia Pacific Urological Cancer Therapeutics Drugs Sales by Region
8.1.2 Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Urological Cancer Therapeutics Drugs Market Facts & Figures by Type
8.3 Asia Pacific Urological Cancer Therapeutics Drugs Market Facts & Figures by Application

9 Latin America
9.1 Latin America Urological Cancer Therapeutics Drugs by Country
9.1.1 Latin America Urological Cancer Therapeutics Drugs Sales by Country
9.1.2 Latin America Urological Cancer Therapeutics Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Urological Cancer Therapeutics Drugs Market Facts & Figures by Type
9.3 Central & South America Urological Cancer Therapeutics Drugs Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Urological Cancer Therapeutics Drugs by Country
10.1.1 Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Country
10.1.2 Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Urological Cancer Therapeutics Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Urological Cancer Therapeutics Drugs Market Facts & Figures by Application

11 Company Profiles
11.1 Novartis
11.1.1 Novartis Corporation Information
11.1.2 Novartis Description, Business Overview and Total Revenue
11.1.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Novartis Urological Cancer Therapeutics Drugs Products Offered
11.1.5 Novartis Recent Development
11.2 Pfizer
11.2.1 Pfizer Corporation Information
11.2.2 Pfizer Description, Business Overview and Total Revenue
11.2.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Pfizer Urological Cancer Therapeutics Drugs Products Offered
11.2.5 Pfizer Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Corporation Information
11.3.2 Johnson & Johnson Description, Business Overview and Total Revenue
11.3.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Johnson & Johnson Urological Cancer Therapeutics Drugs Products Offered
11.3.5 Johnson & Johnson Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Corporation Information
11.4.2 AstraZeneca Description, Business Overview and Total Revenue
11.4.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.4.4 AstraZeneca Urological Cancer Therapeutics Drugs Products Offered
11.4.5 AstraZeneca Recent Development
11.5 Astellas
11.5.1 Astellas Corporation Information
11.5.2 Astellas Description, Business Overview and Total Revenue
11.5.3 Astellas Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Astellas Urological Cancer Therapeutics Drugs Products Offered
11.5.5 Astellas Recent Development
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Corporation Information
11.6.2 Bristol-Myers Squibb Description, Business Overview and Total Revenue
11.6.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Products Offered
11.6.5 Bristol-Myers Squibb Recent Development
11.7 Abbott Laboratories
11.7.1 Abbott Laboratories Corporation Information
11.7.2 Abbott Laboratories Description, Business Overview and Total Revenue
11.7.3 Abbott Laboratories Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Abbott Laboratories Urological Cancer Therapeutics Drugs Products Offered
11.7.5 Abbott Laboratories Recent Development
11.8 Celgene Corporation
11.8.1 Celgene Corporation Corporation Information
11.8.2 Celgene Corporation Description, Business Overview and Total Revenue
11.8.3 Celgene Corporation Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Celgene Corporation Urological Cancer Therapeutics Drugs Products Offered
11.8.5 Celgene Corporation Recent Development
11.9 Dendreon Corporation
11.9.1 Dendreon Corporation Corporation Information
11.9.2 Dendreon Corporation Description, Business Overview and Total Revenue
11.9.3 Dendreon Corporation Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Dendreon Corporation Urological Cancer Therapeutics Drugs Products Offered
11.9.5 Dendreon Corporation Recent Development
11.10 Ferring Pharmaceuticals
11.10.1 Ferring Pharmaceuticals Corporation Information
11.10.2 Ferring Pharmaceuticals Description, Business Overview and Total Revenue
11.10.3 Ferring Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Products Offered
11.10.5 Ferring Pharmaceuticals Recent Development
11.1 Novartis
11.1.1 Novartis Corporation Information
11.1.2 Novartis Description, Business Overview and Total Revenue
11.1.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Novartis Urological Cancer Therapeutics Drugs Products Offered
11.1.5 Novartis Recent Development
11.12 Indevus Pharmaceuticals Inc
11.12.1 Indevus Pharmaceuticals Inc Corporation Information
11.12.2 Indevus Pharmaceuticals Inc Description, Business Overview and Total Revenue
11.12.3 Indevus Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Indevus Pharmaceuticals Inc Products Offered
11.12.5 Indevus Pharmaceuticals Inc Recent Development
11.13 Ipsen
11.13.1 Ipsen Corporation Information
11.13.2 Ipsen Description, Business Overview and Total Revenue
11.13.3 Ipsen Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Ipsen Products Offered
11.13.5 Ipsen Recent Development
11.14 Roche Healthcare
11.14.1 Roche Healthcare Corporation Information
11.14.2 Roche Healthcare Description, Business Overview and Total Revenue
11.14.3 Roche Healthcare Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Roche Healthcare Products Offered
11.14.5 Roche Healthcare Recent Development
11.15 Sanofi S.A.
11.15.1 Sanofi S.A. Corporation Information
11.15.2 Sanofi S.A. Description, Business Overview and Total Revenue
11.15.3 Sanofi S.A. Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Sanofi S.A. Products Offered
11.15.5 Sanofi S.A. Recent Development

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Urological Cancer Therapeutics Drugs Market Estimates and Projections by Region
12.1.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Urological Cancer Therapeutics Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Urological Cancer Therapeutics Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Urological Cancer Therapeutics Drugs Sales Forecast (2021-2026)
12.2.2 North America: Urological Cancer Therapeutics Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Urological Cancer Therapeutics Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Urological Cancer Therapeutics Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Urological Cancer Therapeutics Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Urological Cancer Therapeutics Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Urological Cancer Therapeutics Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Urological Cancer Therapeutics Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Urological Cancer Therapeutics Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Urological Cancer Therapeutics Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Urological Cancer Therapeutics Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Urological Cancer Therapeutics Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Urological Cancer Therapeutics Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Urological Cancer Therapeutics Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Urological Cancer Therapeutics Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Urological Cancer Therapeutics Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Urological Cancer Therapeutics Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Urological Cancer Therapeutics Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Urological Cancer Therapeutics Drugs Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porters Five Forces Analysis
13.5 Primary Interviews with Key Urological Cancer Therapeutics Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Urological Cancer Therapeutics Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details

List of Table

List of Tables
Table 1. Urological Cancer Therapeutics Drugs Market Segments
Table 2. Ranking of Global Top Urological Cancer Therapeutics Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of Xofigo (radium Ra 223 dichloride)
Table 5. Major Manufacturers of Jevtana (cabazitaxel)
Table 6. Major Manufacturers of Inlyta (axitinib)
Table 7. Major Manufacturers of Votrient (pazopanib hydrochloride)
Table 8. Major Manufacturers of Sutent (sunitinib malate)
Table 9. Major Manufacturers of Zytiga (abiraterone acetate)
Table 10. Major Manufacturers of Xtandi (enzalutamide)
Table 11. Major Manufacturers of Opdivo (nivolumab)
Table 12. Major Manufacturers of Provenge (sipuleucel-T)
Table 13. COVID-19 Impact Global Market: (Four Urological Cancer Therapeutics Drugs Market Size Forecast Scenarios)
Table 14. Opportunities and Trends for Urological Cancer Therapeutics Drugs Players in the COVID-19 Landscape
Table 15. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 16. Key Regions/Countries Measures against Covid-19 Impact
Table 17. Proposal for Urological Cancer Therapeutics Drugs Players to Combat Covid-19 Impact
Table 18. Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Application 2020-2026 (K MT)
Table 19. Global Urological Cancer Therapeutics Drugs Market Size by Region (K MT) & (US$ Million): 2020 VS 2026
Table 20. Global Urological Cancer Therapeutics Drugs Sales by Regions 2015-2020 (K MT)
Table 21. Global Urological Cancer Therapeutics Drugs Sales Market Share by Regions (2015-2020)
Table 22. Global Urological Cancer Therapeutics Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 23. Global Urological Cancer Therapeutics Drugs Sales by Manufacturers (2015-2020) (K MT)
Table 24. Global Urological Cancer Therapeutics Drugs Sales Share by Manufacturers (2015-2020)
Table 25. Global Urological Cancer Therapeutics Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 26. Global Urological Cancer Therapeutics Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Urological Cancer Therapeutics Drugs as of 2019)
Table 27. Urological Cancer Therapeutics Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 28. Urological Cancer Therapeutics Drugs Revenue Share by Manufacturers (2015-2020)
Table 29. Key Manufacturers Urological Cancer Therapeutics Drugs Price (2015-2020) (USD/MT)
Table 30. Urological Cancer Therapeutics Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 31. Manufacturers Urological Cancer Therapeutics Drugs Product Type
Table 32. Date of International Manufacturers Enter into Urological Cancer Therapeutics Drugs Market
Table 33. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 34. Global Urological Cancer Therapeutics Drugs Sales by Type (2015-2020) (K MT)
Table 35. Global Urological Cancer Therapeutics Drugs Sales Share by Type (2015-2020)
Table 36. Global Urological Cancer Therapeutics Drugs Revenue by Type (2015-2020) (US$ Million)
Table 37. Global Urological Cancer Therapeutics Drugs Revenue Share by Type (2015-2020)
Table 38. Urological Cancer Therapeutics Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 39. Global Urological Cancer Therapeutics Drugs Sales by Application (2015-2020) (K MT)
Table 40. Global Urological Cancer Therapeutics Drugs Sales Share by Application (2015-2020)
Table 41. North America Urological Cancer Therapeutics Drugs Sales by Country (2015-2020) (K MT)
Table 42. North America Urological Cancer Therapeutics Drugs Sales Market Share by Country (2015-2020)
Table 43. North America Urological Cancer Therapeutics Drugs Revenue by Country (2015-2020) (US$ Million)
Table 44. North America Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2015-2020)
Table 45. North America Urological Cancer Therapeutics Drugs Sales by Type (2015-2020) (K MT)
Table 46. North America Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
Table 47. North America Urological Cancer Therapeutics Drugs Sales by Application (2015-2020) (K MT)
Table 48. North America Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
Table 49. Europe Urological Cancer Therapeutics Drugs Sales by Country (2015-2020) (K MT)
Table 50. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Country (2015-2020)
Table 51. Europe Urological Cancer Therapeutics Drugs Revenue by Country (2015-2020) (US$ Million)
Table 52. Europe Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2015-2020)
Table 53. Europe Urological Cancer Therapeutics Drugs Sales by Type (2015-2020) (K MT)
Table 54. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
Table 55. Europe Urological Cancer Therapeutics Drugs Sales by Application (2015-2020) (K MT)
Table 56. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
Table 57. Asia Pacific Urological Cancer Therapeutics Drugs Sales by Region (2015-2020) (K MT)
Table 58. Asia Pacific Urological Cancer Therapeutics Drugs Sales Market Share by Region (2015-2020)
Table 59. Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Region (2015-2020) (US$ Million)
Table 60. Asia Pacific Urological Cancer Therapeutics Drugs Revenue Market Share by Region (2015-2020)
Table 61. Asia Pacific Urological Cancer Therapeutics Drugs Sales by Type (2015-2020) (K MT)
Table 62. Asia Pacific Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
Table 63. Asia Pacific Urological Cancer Therapeutics Drugs Sales by Application (2015-2020) (K MT)
Table 64. Asia Pacific Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
Table 65. Latin America Urological Cancer Therapeutics Drugs Sales by Country (2015-2020) (K MT)
Table 66. Latin America Urological Cancer Therapeutics Drugs Sales Market Share by Country (2015-2020)
Table 67. Latin Americaa Urological Cancer Therapeutics Drugs Revenue by Country (2015-2020) (US$ Million)
Table 68. Latin America Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2015-2020)
Table 69. Latin America Urological Cancer Therapeutics Drugs Sales by Type (2015-2020) (K MT)
Table 70. Latin America Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
Table 71. Latin America Urological Cancer Therapeutics Drugs Sales by Application (2015-2020) (K MT)
Table 72. Latin America Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
Table 73. Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Country (2015-2020) (K MT)
Table 74. Middle East and Africa Urological Cancer Therapeutics Drugs Sales Market Share by Country (2015-2020)
Table 75. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Country (2015-2020) (US$ Million)
Table 76. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2015-2020)
Table 77. Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Type (2015-2020) (K MT)
Table 78. Middle East and Africa Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
Table 79. Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Application (2015-2020) (K MT)
Table 80. Middle East and Africa Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
Table 81. Novartis Corporation Information
Table 82. Novartis Description and Major Businesses
Table 83. Novartis Urological Cancer Therapeutics Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 84. Novartis Product
Table 85. Novartis Recent Development
Table 86. Pfizer Corporation Information
Table 87. Pfizer Description and Major Businesses
Table 88. Pfizer Urological Cancer Therapeutics Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 89. Pfizer Product
Table 90. Pfizer Recent Development
Table 91. Johnson & Johnson Corporation Information
Table 92. Johnson & Johnson Description and Major Businesses
Table 93. Johnson & Johnson Urological Cancer Therapeutics Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 94. Johnson & Johnson Product
Table 95. Johnson & Johnson Recent Development
Table 96. AstraZeneca Corporation Information
Table 97. AstraZeneca Description and Major Businesses
Table 98. AstraZeneca Urological Cancer Therapeutics Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 99. AstraZeneca Product
Table 100. AstraZeneca Recent Development
Table 101. Astellas Corporation Information
Table 102. Astellas Description and Major Businesses
Table 103. Astellas Urological Cancer Therapeutics Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 104. Astellas Product
Table 105. Astellas Recent Development
Table 106. Bristol-Myers Squibb Corporation Information
Table 107. Bristol-Myers Squibb Description and Major Businesses
Table 108. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 109. Bristol-Myers Squibb Product
Table 110. Bristol-Myers Squibb Recent Development
Table 111. Abbott Laboratories Corporation Information
Table 112. Abbott Laboratories Description and Major Businesses
Table 113. Abbott Laboratories Urological Cancer Therapeutics Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 114. Abbott Laboratories Product
Table 115. Abbott Laboratories Recent Development
Table 116. Celgene Corporation Corporation Information
Table 117. Celgene Corporation Description and Major Businesses
Table 118. Celgene Corporation Urological Cancer Therapeutics Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 119. Celgene Corporation Product
Table 120. Celgene Corporation Recent Development
Table 121. Dendreon Corporation Corporation Information
Table 122. Dendreon Corporation Description and Major Businesses
Table 123. Dendreon Corporation Urological Cancer Therapeutics Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 124. Dendreon Corporation Product
Table 125. Dendreon Corporation Recent Development
Table 126. Ferring Pharmaceuticals Corporation Information
Table 127. Ferring Pharmaceuticals Description and Major Businesses
Table 128. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 129. Ferring Pharmaceuticals Product
Table 130. Ferring Pharmaceuticals Recent Development
Table 131. GlaxoSmithKline plc Corporation Information
Table 132. GlaxoSmithKline plc Description and Major Businesses
Table 133. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 134. GlaxoSmithKline plc Product
Table 135. GlaxoSmithKline plc Recent Development
Table 136. Indevus Pharmaceuticals Inc Corporation Information
Table 137. Indevus Pharmaceuticals Inc Description and Major Businesses
Table 138. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 139. Indevus Pharmaceuticals Inc Product
Table 140. Indevus Pharmaceuticals Inc Recent Development
Table 141. Ipsen Corporation Information
Table 142. Ipsen Description and Major Businesses
Table 143. Ipsen Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 144. Ipsen Product
Table 145. Ipsen Recent Development
Table 146. Roche Healthcare Corporation Information
Table 147. Roche Healthcare Description and Major Businesses
Table 148. Roche Healthcare Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 149. Roche Healthcare Product
Table 150. Roche Healthcare Recent Development
Table 151. Sanofi S.A. Corporation Information
Table 152. Sanofi S.A. Description and Major Businesses
Table 153. Sanofi S.A. Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 154. Sanofi S.A. Product
Table 155. Sanofi S.A. Recent Development
Table 156. Global Urological Cancer Therapeutics Drugs Sales Forecast by Regions (2021-2026) (K MT)
Table 157. Global Urological Cancer Therapeutics Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 158. Global Urological Cancer Therapeutics Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 159. Global Urological Cancer Therapeutics Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 160. North America: Urological Cancer Therapeutics Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 161. North America: Urological Cancer Therapeutics Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 162. Europe: Urological Cancer Therapeutics Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 163. Europe: Urological Cancer Therapeutics Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 164. Asia Pacific: Urological Cancer Therapeutics Drugs Sales Forecast by Region (2021-2026) (K MT)
Table 165. Asia Pacific: Urological Cancer Therapeutics Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 166. Latin America: Urological Cancer Therapeutics Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 167. Latin America: Urological Cancer Therapeutics Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 168. Middle East and Africa: Urological Cancer Therapeutics Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 169. Middle East and Africa: Urological Cancer Therapeutics Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 170. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 171. Key Challenges
Table 172. Market Risks
Table 173. Main Points Interviewed from Key Urological Cancer Therapeutics Drugs Players
Table 174. Urological Cancer Therapeutics Drugs Customers List
Table 175. Urological Cancer Therapeutics Drugs Distributors List
Table 176. Research Programs/Design for This Report
Table 177. Key Data Information from Secondary Sources
Table 178. Key Data Information from Primary Sources
List of Figures
Figure 1. Urological Cancer Therapeutics Drugs Product Picture
Figure 2. Global Urological Cancer Therapeutics Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Xofigo (radium Ra 223 dichloride) Product Picture
Figure 4. Jevtana (cabazitaxel) Product Picture
Figure 5. Inlyta (axitinib) Product Picture
Figure 6. Votrient (pazopanib hydrochloride) Product Picture
Figure 7. Sutent (sunitinib malate) Product Picture
Figure 8. Zytiga (abiraterone acetate) Product Picture
Figure 9. Xtandi (enzalutamide) Product Picture
Figure 10. Opdivo (nivolumab) Product Picture
Figure 11. Provenge (sipuleucel-T) Product Picture
Figure 12. Global Urological Cancer Therapeutics Drugs Sales Market Share by Application in 2020 & 2026
Figure 13. Hospital
Figure 14. Medical Research Laboratory
Figure 15. Others
Figure 16. Urological Cancer Therapeutics Drugs Report Years Considered
Figure 17. Global Urological Cancer Therapeutics Drugs Market Size 2015-2026 (US$ Million)
Figure 18. Global Urological Cancer Therapeutics Drugs Sales 2015-2026 (K MT)
Figure 19. Global Urological Cancer Therapeutics Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 20. Global Urological Cancer Therapeutics Drugs Sales Market Share by Region (2015-2020)
Figure 21. Global Urological Cancer Therapeutics Drugs Sales Market Share by Region in 2019
Figure 22. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Region (2015-2020)
Figure 23. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Region in 2019
Figure 24. Global Urological Cancer Therapeutics Drugs Sales Share by Manufacturer in 2019
Figure 25. The Top 10 and 5 Players Market Share by Urological Cancer Therapeutics Drugs Revenue in 2019
Figure 26. Urological Cancer Therapeutics Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 27. Global Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
Figure 28. Global Urological Cancer Therapeutics Drugs Sales Market Share by Type in 2019
Figure 29. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2015-2020)
Figure 30. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type in 2019
Figure 31. Global Urological Cancer Therapeutics Drugs Market Share by Price Range (2015-2020)
Figure 32. Global Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
Figure 33. Global Urological Cancer Therapeutics Drugs Sales Market Share by Application in 2019
Figure 34. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2015-2020)
Figure 35. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Application in 2019
Figure 36. North America Urological Cancer Therapeutics Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 37. North America Urological Cancer Therapeutics Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 38. North America Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2019
Figure 39. North America Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2019
Figure 40. U.S. Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 41. U.S. Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 42. Canada Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 43. Canada Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 44. North America Urological Cancer Therapeutics Drugs Market Share by Type in 2019
Figure 45. North America Urological Cancer Therapeutics Drugs Market Share by Application in 2019
Figure 46. Europe Urological Cancer Therapeutics Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 47. Europe Urological Cancer Therapeutics Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 48. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2019
Figure 49. Europe Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2019
Figure 50. Germany Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 51. Germany Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. France Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 53. France Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. U.K. Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 55. U.K. Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Italy Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 57. Italy Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. Russia Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 59. Russia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 60. Europe Urological Cancer Therapeutics Drugs Market Share by Type in 2019
Figure 61. Europe Urological Cancer Therapeutics Drugs Market Share by Application in 2019
Figure 62. Asia Pacific Urological Cancer Therapeutics Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 63. Asia Pacific Urological Cancer Therapeutics Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 64. Asia Pacific Urological Cancer Therapeutics Drugs Sales Market Share by Region in 2019
Figure 65. Asia Pacific Urological Cancer Therapeutics Drugs Revenue Market Share by Region in 2019
Figure 66. China Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 67. China Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Japan Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 69. Japan Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. South Korea Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 71. South Korea Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. India Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 73. India Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Australia Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 75. Australia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Taiwan Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 77. Taiwan Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Indonesia Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 79. Indonesia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Thailand Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 81. Thailand Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Malaysia Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 83. Malaysia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Philippines Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 85. Philippines Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 86. Vietnam Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 87. Vietnam Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 88. Asia Pacific Urological Cancer Therapeutics Drugs Market Share by Type in 2019
Figure 89. Asia Pacific Urological Cancer Therapeutics Drugs Market Share by Application in 2019
Figure 90. Latin America Urological Cancer Therapeutics Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 91. Latin America Urological Cancer Therapeutics Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 92. Latin America Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2019
Figure 93. Latin America Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2019
Figure 94. Mexico Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 95. Mexico Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Brazil Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 97. Brazil Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 98. Argentina Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 99. Argentina Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 100. Latin America Urological Cancer Therapeutics Drugs Market Share by Type in 2019
Figure 101. Latin America Urological Cancer Therapeutics Drugs Market Share by Application in 2019
Figure 102. Middle East and Africa Urological Cancer Therapeutics Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 103. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 104. Middle East and Africa Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2019
Figure 105. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2019
Figure 106. Turkey Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 107. Turkey Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Saudi Arabia Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 109. Saudi Arabia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 110. U.A.E Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 111. U.A.E Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 112. Middle East and Africa Urological Cancer Therapeutics Drugs Market Share by Type in 2019
Figure 113. Middle East and Africa Urological Cancer Therapeutics Drugs Market Share by Application in 2019
Figure 114. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 115. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 116. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 117. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 118. Astellas Total Revenue (US$ Million): 2019 Compared with 2018
Figure 119. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 120. Abbott Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 121. Celgene Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 122. Dendreon Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 123. Ferring Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 124. GlaxoSmithKline plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 125. Indevus Pharmaceuticals Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 126. Ipsen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 127. Roche Healthcare Total Revenue (US$ Million): 2019 Compared with 2018
Figure 128. Sanofi S.A. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 129. North America Urological Cancer Therapeutics Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 130. North America Urological Cancer Therapeutics Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 131. Europe Urological Cancer Therapeutics Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 132. Europe Urological Cancer Therapeutics Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 133. Asia Pacific Urological Cancer Therapeutics Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 134. Asia Pacific Urological Cancer Therapeutics Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 135. Latin America Urological Cancer Therapeutics Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 136. Latin America Urological Cancer Therapeutics Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 137. Middle East and Africa Urological Cancer Therapeutics Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 138. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 139. Porter's Five Forces Analysis
Figure 140. Channels of Distribution
Figure 141. Distributors Profiles
Figure 142. Bottom-up and Top-down Approaches for This Report
Figure 143. Data Triangulation
Figure 144. Key Executives Interviewed

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 3900
$ 5850

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top